Although VHL-defective cancers can be targeted with clinical success by inhibiting its downstream effector HIF1a or VEGF-driven angiogenesis [62], we hypothesize that VHL function could be restored, at least in part, through ASO-mediated transcript modification. This evidence concerns the gene VHL and cancer.